NCT02797847 - A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 7, 2016

Primary Completion Date

January 12, 2018

Study Completion Date

January 12, 2018

Conditions

Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)

Interventions

DRUG

ALN-TTRSC02

Ascending doses of ALN-TTRSC02 by subcutaneous (SC) injection

DRUG

Sterile Normal Saline (0.9% NaCl)

Calculated volume to match active comparator

Trial Locations (1)

Clinical Trial Site, London